Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.K. PSE Rx only?

This article was originally published in The Tan Sheet

Executive Summary

The Proprietary Association of Great Britain says the U.K. Medicine and Healthcare products Regulatory Agency should not make pseudoephedrine prescription-only in an April 25 release. In March MHRA proposed Rx-only status for PSE- and ephedrine-containing OTCs to prevent the manufacture of methamphetamine (1"The Tan Sheet" March 12, 2007, p. 4). "We urge the government not to take disproportionate measures to control pseudoephedrine that would affect legitimate usage and consumer needs," PAGB says. The group encourages PSE restrictions similar to U.S. measures such as sales limits and behind-the-counter or locked cabinet storage (2"The Tan Sheet" March 6, 2006, p. 5)...

You may also be interested in...

U.K. Proposes Prescription-Only Status For Pseudoephedrine Products

The U.K. Medicines and Healthcare products Regulatory Agency is proposing prescription status for pseudoephedrine- and ephedrine-containing drugs in order to prevent the illegal manufacture of methamphetamine

Pseudoephedrine Will Be Behind The Counter Across The Country By October

Retailers will have to be prepared to enforce monthly gram purchase limits on pseudoephedrine products by mid-April, once meth control provisions of the Patriot Act reauthorization bill go into effect

FDA Talks Tough On Complete Response Extensions

The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts